+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hanmi Pharmaceuticals Co Ltd (128940) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 55 Pages
  • November 2022
  • Region: Global
  • GlobalData
  • ID: 4282205
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Hanmi Pharmaceuticals Co Ltd (128940) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Hanmi Pharmaceuticals Co Ltd (Hanmi Pharmaceuticals), a subsidiary of Hanmi Science Co Ltd, develops prescription drugs and over the counter (OTC) drugs. The company's prescription drugs include antibiotics, antidiarrheal, osteoporosis, liver supplements and antiemetics. It provides OTC products such as nutritional supplements, calcium supplement, vitamins, among others. Hanmi Pharmaceuticals products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others. The company operates through its manufacturing facilities located in Hwaseong, Songpa and Pyeongtaek, South Korea. Hanmi Pharmaceuticals is headquartered in Seoul, South Korea.

Hanmi Pharmaceuticals Co Ltd Key Recent Developments

  • May 22, 2022: Hanmi Fine Chemical launches 'high-tech CDMO' business
  • Mar 10, 2022: Spectrum Pharmaceuticals Appoints Juhyun Lim of Hanmi Pharmaceutical to Board of Directors
  • Oct 27, 2021: Beijing Hanmi Pharmaceuticals opens new fields of pharmaceutical & storage automation-interview with completion of intelligent automated warehouse & pharmaceutical production line in 2021
  • Jul 29, 2021: Hanmi Pharm achieves strong results in the second quarter through COVID-19

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Hanmi Pharmaceuticals Co Ltd - Key Facts
  • Hanmi Pharmaceuticals Co Ltd - Key Employees
  • Hanmi Pharmaceuticals Co Ltd - Key Employee Biographies
  • Hanmi Pharmaceuticals Co Ltd - Major Products and Services
  • Hanmi Pharmaceuticals Co Ltd - History
  • Hanmi Pharmaceuticals Co Ltd - Company Statement
  • Hanmi Pharmaceuticals Co Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Hanmi Pharmaceuticals Co Ltd - Business Description
  • Product Category: Licensing Royalties
  • Performance
  • Product Category: Other Sales
  • Performance
  • Product Category: Beijing Hanmi
  • Overview
  • Performance
  • Key Stats
  • Product Category: Hanmi Fine Chem
  • Overview
  • Performance
  • Product Category: Hanmi Pharm
  • Overview
  • Performance
  • R&D Overview
  • Hanmi Pharmaceuticals Co Ltd - Corporate Strategy
  • Hanmi Pharmaceuticals Co Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Hanmi Pharmaceuticals Co Ltd - Strengths
  • Hanmi Pharmaceuticals Co Ltd - Weaknesses
  • Hanmi Pharmaceuticals Co Ltd - Opportunities
  • Hanmi Pharmaceuticals Co Ltd - Threats
  • Hanmi Pharmaceuticals Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Hanmi Pharmaceuticals Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 22, 2022: Hanmi Fine Chemical launches 'high-tech CDMO' business
  • Mar 10, 2022: Spectrum Pharmaceuticals Appoints Juhyun Lim of Hanmi Pharmaceutical to Board of Directors
  • Oct 27, 2021: Beijing Hanmi Pharmaceuticals opens new fields of pharmaceutical & storage automation-interview with completion of intelligent automated warehouse & pharmaceutical production line in 2021
  • Jul 29, 2021: Hanmi Pharm achieves strong results in the second quarter through COVID-19
  • Jul 01, 2021: Korea National Institute of Health (KNIH) conducts field inspection of companies with mRNA technology
  • Feb 12, 2021: Hanmi presents solution package for coping with COVID-19, including the mass production of nucleic acid vaccines
  • Feb 04, 2021: Hanmi Pharm last year’s sales of KRW 1.75.9 trillion and investment of KRW 226.1 billion in R&D
  • Jan 29, 2021: JVM achieved good results last year with sales of 115.4 billion won and operating profit of 15.7 billion won
  • Jan 18, 2021: Hanmi Pharmaceutical expects U.S. FDA approval for 2 new drugs
  • Jan 12, 2021: Hanmi presents solution package for coping with COVID-19, including the mass production of nucleic acid vaccines (DNA/mRNA vaccine)
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Hanmi Pharmaceuticals Co Ltd, Key Facts
  • Hanmi Pharmaceuticals Co Ltd, Key Employees
  • Hanmi Pharmaceuticals Co Ltd, Key Employee Biographies
  • Hanmi Pharmaceuticals Co Ltd, Major Products and Services
  • Hanmi Pharmaceuticals Co Ltd, History
  • Hanmi Pharmaceuticals Co Ltd, Other Locations
  • Hanmi Pharmaceuticals Co Ltd, Key Competitors
  • Hanmi Pharmaceuticals Co Ltd, Ratios based on current share price
  • Hanmi Pharmaceuticals Co Ltd, Annual Ratios
  • Hanmi Pharmaceuticals Co Ltd, Interim Ratios
  • Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Hanmi Pharmaceuticals Co Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Hanmi Pharmaceuticals Co Ltd, Performance Chart (2017 - 2021)
  • Hanmi Pharmaceuticals Co Ltd, Ratio Charts
  • Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • GC Biopharma Corp
  • Daewoong Pharmaceutical Co Ltd
  • Dong-A Socio Holdings Co Ltd
  • JW Holdings Corp
  • Yuhan Corp
  • Dong-A Socio Holdings Co Ltd
  • Yuhan Corp
  • GC Biopharma Corp
  • Daewoong Pharmaceutical Co Ltd
  • JW Holdings Corp